由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
Immigration版 - 【精华全书】经验+RL/PL模板【长期更新】
相关主题
麻烦大家帮我看一下EB1B单位的sponsorship letter再请教:关于Journal的ranking percentage,化学的尤其请进
怎么准备那个details of significance of journalEB1a approve后PL分享
攒人品,发EB1A PL模板贡献RFE模板: EB1a TSC PP RFE approved
journal 的circulation需要放在申请材料里吗回报本版I-140-NSC-PP-Approved today
分享我的 Index of ExhibitsDIY 新手提问:journal 介绍
贡献一篇主编给小编的支持信模板审稿的journal需要每个都给exhibit里面介绍吗?
TSC 485 报绿,送绿装publication里要把paper全列出来吗?
请问:怎么吹胡发表我的文章的Journal?问个网页打印的问题
相关话题的讨论汇总
话题: exhibit话题: dr话题: journal话题: research话题: angellee
进入Immigration版参与讨论
1 (共1页)
r****y
发帖数: 263
1
收集于落地生根版
由remedy长期更新
模板收入空间备份
祝大家一切都顺利
r****y
发帖数: 263
2
收入经验类别 http://user.qzone.qq.com/2915799706/2
从年初开始准备140就一直上这个版,从一开始一无所知到现在也对这些专用名字如数
家珍,真的非常感谢版上大家的帮助和祝福。4-14-2014,寄出材料;4-17-2014,RD;4-
21-2014律师收到e-mail receipt,之后网上状态一直为acceptance直到4-28-2014早上
直接跳到post decision。刚寄出材料及等待的过程中还发了好几个帖子求祝福。
本人背景如下:
生物医学专业,美国三流大学phd毕业,毕业到现在差两个月一年,毕业后在原实验室
research scientist至今。
1.文章19篇,英文15,中文4,一作11(10英一中),IF2-12不等,book chapter1个。
没什么牛文,亮点也就是有几个杂志在分类排名中1,2,3名。会议摘要9次,6次在本领
域最top会议,其中两次oral。
2.引用google scholar上101次,独立引用65,这个我自认为是短板,因为文章大多是
13年后发的,不过分布还算广泛,22个国家和地区,油灯图看上去也不算很惨,所以用
了油灯图,也列了表格,具体的统计了每篇文章的引用次数,独立引用次数,及引用的
地理分布。另外还做了一张表格列出了impact factors of the journals that cited
Dr. 's article,作图中发现有一个30分的杂志引用了我的文章,算是一个小亮点吧,
注意这张表格中从impact factor从大到小的顺序排列杂志。推荐信一共8封,均为独立
推荐。美国4封(包括一杂志副主编,提到了为何选我做审稿人),这四人算中牛吧,
均为director级别;日本一封,assistant professor,和我做的东西非常相关,推荐
信中讲了很多一般人不太懂的东西,律师说要改,但想着推荐人和我做的非常对口,就
没改;中国一封,工程院院士;欧洲及澳大利亚各一封,也是director级别的。还交了
一些别人向我要文章,请求帮助解决实验问题,文章中的图被抗体网站置顶的e-mail.
还有一个project investigator的头衔,其实就是老板给的,不知道律师放在哪个里面
claim了。
3.审稿20个杂志,33篇文章44次。另外editor board一个,小破杂志,无影响因子,
invited editor一个,IF3点几。另外大学里undergraduate research day moderator
两次,也不知道有没有用,要了学校副校长的确认信交上去了。
4.律师还claim了奖项这一项,当时问她是否可以不claim,怕RFE,律师说没事,把该给
的证据都交上去,IO不承认就不承认,但不会招致RFE。我就4个小破奖,其中两个是
travel grant,不过从网站上找到了该奖的介绍,说是发给学生,薄后及新PI的,介绍
中还说要top20%才能得这奖,反正也把这个介绍打印了交上去了。背景大概就这样,我
觉得很重要的一点是不管你claim什么,都一定要提供证据,譬如我问副校长要的确认
信,grant负责人给的project invistigator的确认信等等。这点我律师做的非常好,
所有的证据检查的非常仔细,如果没律师就自己多注意了。最后祝大家都早日approve
。准备485中肯定还有很多问题要上来请教。再次谢过!
r****y
发帖数: 263
3
收入经验类别http://user.qzone.qq.com/2915799706/2
12/14 e-filing
12/20 收到 email 说 RD 是12/19
此后状态一直是 acceptance。
今天一大早起床发现TSC昨晚(12/30)发来的email说approved了,PD为 12/16。
机电专业(mechatronics)
2007年以来,期刊及会议录发文22篇(13篇一作,8篇二作,1篇三作)
34次引用,其中22次为独立引用(Google Scholar)
书1本(二作,全书)
专利1个
审稿23篇
以下为经验分享。为了节省大家时间,我先把通用经验写出来,以后有时间再细谈不可
复制的个人特殊经验。
首先要感谢LD长达10年的不懈敦促和鼓励。其次要感谢本版所有热心人的经验分享。
通用经验
1. 请律师还是DIY
建议先找几个律师免费评估。版上的这些律师都很热心,回复也很快。最好电话谈谈。
如果律师“面”有难色(我就是此类),说明你的情况很棘手,虽然律师不会拒绝,但
是你可以考虑DIY了。由于我的专业不热,引用率低,没有大奖,书12月才出版,专利
没有商业化,律师的初步评估让我感到很沮丧。我选择了DIY,因为第一,最有条件和
动力在自己身上找闪光点的是自己;第二,最了解自己的也是自己。
如果把申请EB1A比作采矿的话,律师就是拥有长期成功探矿和采矿经验及先进设备的国
际集团;而你自己则是一个只有一个破镐,一个破筛,从祖上传说中得知村里后山可能
有金矿,靠看太阳和星星来定方位,根据神话故事来断定后山地质年龄和结构的本土砖
家。
像我这种只在小河床里埋着些许小沙金的情况,说实话国际矿业集团也很为难。投入大
,风险又大,又不忍拒绝。而我自己则可以在没有任何负担的情况下,拿个破筛到河边
慢慢筛,犯懒了,就休息休息。找到了一粒小沙金,用显微镜放大一下,或说形状是世
界独一无二;或说上面似乎刻有比玛雅人末世预言还准的原子甲骨文。然后接着找下一
粒...
下面的第5点也会提到请律师的一个决定因素。
2. PP 还是非 PP
有一位网友回复的好“伸头也是一刀,缩头也是一刀”。
LD说“早点办了吧!”
所以这个问题的关键其实是"你自己梳装打扮好了吗?"
3. 从哪开始
也许是我考古不够细致,也许是我孤陋寡闻,我直接从写推荐信开始入手,走了很多弯
路。
正确的步骤应该是从定位你的专业方向开始。
所谓纲举目张,申请资料的纲很重要,它决定了推荐信怎么写,申请信怎么组织。很多
人看到这里可能会笑我了。没错,专业方向清晰明了的人不需要这么麻烦,但是别忘了
在城乡结合处还有很多专业方向语焉不详的游民。而且为了让你发文的期刊排名好看,
往往需要缩小“定义域”,这就更需要花一番心思了。工程类的读者应该明白我在说什
么。
所以首先就到 http://wokinfo.com(可在教育网免费注册帐号)或者 http://www.scimagojr.com 查查你发文期刊所属专业方向及专业方向内排名。很多期刊分属多种专业方向,而且在每种专业方向的排名不一样。我到了申请信写到后半部分才进行这一步,然后发现我发文的一个期刊在某一个方向上排名第一,结果我前面写的大量说辞全部重写,推荐信也重写。
我之所以推荐 http://wokinfo.com ,是因为它分的专业方向对我很有利。
4. 如何定专业方向
前面已经提到了,专业方向应该先根据期刊排名数据库的最佳结果来定。这里还存在有
两个问题。第一,如果是跨学科专业怎么选?第二,如果排名数据库没有对口的研究方
向的排名怎么办?
这两个问题困扰了我很久很久很久。
关于第一个问题。起初我选择 mechatronics。LD说这个在美国不热,很少听说,IO一
看这么冷的名字,可能会想对美国没啥用。于是我开始考虑分拆。一开是我是根据自己
的直觉分拆,觉得很不错。等写到申请信后面要列期刊排名了,发现分的不伦不类,而
且排名也不佳。最后根据排名数据库的资料在电子类选了个排名好的方向。但对于机械
类,仍然没找到好方向,这就引出了上面提到的第二个问题。
关于第二个问题。我花了很多时间在各种期刊排名数据库中找关于机械类的有利方向,
始终没找到。最后我干脆将 http://wokinfo.com 列的一百多个机械工程类期刊排名表打印出来,然后用彩笔把与我发文期刊标题和内容类似的期刊全部划上,然后在原排名表旁边手工再细分排名。这样我发文期刊的排名就到第一了。这个我承认有点剑走偏锋了,我当时担心会招来 RFE 要求解释为什么仅凭期刊名字就划分方向了。需要说明的一点是 http://wokinfo.com 的期刊排名列表用的是期刊名字的缩写,为了不招来 RFE,我特地做了一张全称和缩写的对照表。可能所有期刊的名字本身还都很详细,而且我最后选择的方向名字在这些期刊名中都有出现,所以最后没招来 RFE。
5. 尽信模板则不如无模板
请大家不要误会这个小标题。没有模板和经验分享(祖上关于村里后山金矿的传说以及
关于后山来历的神话故事),我大概现在还处在抱怨雇主对我不公平可我又不能说狠话
的伤肝伤脾状态。
但是我要强调的是,模板和经验只能领你入门,而且帮你完成80%的工作,还有20%的工
作需要你根据自身的情况发挥你的“特殊人才”来完成。每个人都有自己的优势和劣势
,模板和经验分享不可能面面俱到,所以一定要从模板和经验中抽取出思想和主义来,
然后用思想和主义武装自己来完成剩下的20%工作。这20%很可能是决定成败的部分。如
果你对自己完成这20%没信心,你可以考虑找律师了。
曾经有一到两周的时间,我一味的研读模板和经验,越读越找不到我要的答案。最后掩
卷沉思,回想主旨大意,然后就有了上面分享的第 4 点。
6. 美国利益是关键
已经有很多经验谈到这点了。既然申请的目标是美国绿卡,最有说服力的当然是你跟美
国利益的密切关系。所以,能找到美国利益的代言人为你美言几句,那是胜过千言万语
。我自己无心插柳结识了一位美国国家级研究机构资深研究员,一起写论文和书。我相
信他的推荐信
起到了决定性的作用。另外,我认识的一个朋友说他的申请获批是因为有一封来自美国
能源部的推荐信。
所以我建议论文和引用数装不满一箩筐的读者可以多花些心思结交美国利益代言人。在
各种会议和研讨会上这些人应该不少。除了跟炸药奖得主级别的教授套瓷以外,和这些
美国利益代言人套瓷的效果会更让你意想不到。
7. 重要思想和主义
我个人受益最深的文章是 ilovescu (flyfly2) 写的“EB1A I-140: 一条龙教你如何博
取IO的眼球”。该文章被收录在精华区的“I-140 杂项”的第60篇。
文中提到的要点(“简洁美观”,“一个中心,三个基本点”,“挥刀断臂”,“软硬
兼施”,“表格”)都在我的申请中得到了认真贯彻并且最后真的应验了。我的申请信
简洁得非常骨感。总共10页多一点点。
接下来我想强调一下所谓的 totality 。
很多经验都是谈论你在 I am an alien of extraordinary ability 部分 claim 的几
项加起来的 totality。我想分享的是不要忘了还有顶层 claim 中的其他两项:I will
continue to work in the area of extraordinary ability in the United States
and contribute to its advancement,以及 My continuous stay will
substantially benefit the United States。这两项被卡壳的屡见不鲜。
我在工业界就职,所以 employment letter 是证明你会继续在自己领域内奋进的最好
材料。很多人(包括我自己)会问,我申请绿卡就说明我跟雇主关系不太好了,我还自
投罗网要 employment letter 干吗?请注意, employment letter 是你的权利,而且
用途很广,不一定是用来申请绿卡,稍加掩饰,就可以不打草惊蛇的获得。我一开始愚
蠢的请 HR 写一封巨细无遗的信(各位看官引以为戒),结果引起高度怀疑和 HR 的盘
问(他们一定发觉了我的意图然后通知了我的上司)。后来我纠正说给父母申请旅游签
证用(我推荐使用的方法),你们随便写,慢慢写。后来 HR 写了一封寥寥数字的类似
于此人还健在的证明信。我要说的是,这就足够了。剩下的就是用你的巨额工资单来证
明你的强大存在,同时在你的 CV 中大书特书你在工作中的丰功伟绩和宏图展望,再辅
以公司的背景介绍。另外,有一封推荐信我特意写的是对我就职的领域的吹捧。
关于证明你会继续造福美国,我就简单引用几封推荐信中的几段原文。所以在酝酿推荐
信时,其中的两三封中就要注意借美国专家的口来为此处埋附笔。比如业界面临的诸项
挑战,非此牛人不可解决。此牛业已取得的成果其实就是美国政府意欲重振旗鼓的有利
工具,此牛稍适改进,就可帮美国夺回盟主地位。吹不死,就往死里吹。
8. 用事实和细节说话
必须得承认,这是不容易做到的。尤其是当你写到第三篇推荐信的时候,你除了想吐,
似乎已经没有别的了。但是,请记住,不是玩笑话,“吐阿吐阿就习惯了”。上面的第
7 点最后我提到了怎么把推荐信写的多元化。
我在推荐信和申请信中没有用任何“top young talent”之类的主观评价。而是用细节
和事实说话。比如,“能在电子和机械两大领域都取得如此建树的人,我没见过”,“
他所开创的符号求导为前提,连续性方程为形式,约束方程为嵌入式自检验的设计方法
,以及基于拉格朗日动力学方程和数值微分的仿真方法完爆传统的手工试探纠错法”。
一开始我担心写的太专业细致会招不测,结果恰恰相反。被“top young scientist”
折磨得不行了的 IO 似乎更喜欢直接忽略他/她们专业承受力的细节描述。你看看 CSI
美剧和 Inception 电影中排山倒海的专业术语就知道老美有多么喜欢专业级的作品了
。其实换一个角度,如果我收到一篇充满术语的文章,我会认为作者是把我当成业界专
家才会对我拽文,于是自豪感和受尊重感徒然而生。当然,凡是有个度,通篇之乎者也
我也不保证后果如何了。
r****y
发帖数: 263
4
收入经验类别http://user.qzone.qq.com/2915799706/blog/1398824543
上一周把140, PP, 485 都寄出去了(分了三次寄不同地方,有些折腾啊)。收到
email说PP开始,真诚向版上的XDJM求祝福,也祝大家早绿!
准备材料这半年在版上学了很多,在这里我也把自己的一些小经验分享一下,希望对大
家有所帮助。
1. 要推荐信:根据前人的经验,我都是周一,周二晚上把要推荐信的email发出。
Email的内容也是根据版上的模版做了点小改动。可是最初的3-4封信都石沉大海,没有
任何回音。我想来想去,很可能牛人们这样的信收的太多,不相干的人也许根本不会把
email点开看。于是我把邮件的标题改成了“Support letter inquiry (former
graduate student of Dr. xx (or postdoc of Dr. xx))”。我要信的目标也主要是
那些比较熟悉我老板的人 。不知道是改标题还是改目标起了作用,后来再发的邮件全
都一举中的,并且基本都在我发去draft后的2-3天收到了签好的推荐信。以下是我要推
荐信的email,因为信比较长,我highlight了重点,好让收信人短时间了解我的目的。
发出去的Email都大致相同,只是套近乎的第一段有所改动。
Dear Dr. xx,
My name is xx. I worked on the xxx for my graduate research under the
mentorship of Dr. xx in the University of xx. Specifically, I studied the
role of xx in the xx. Because of the research interest, I have been
following your research and publications for years. I truly admire your
tremendous efforts and achievements toward the better understanding and
treatment of xx and I felt honored that my papers on xx (journal..) were
cited in your works.
After graduating from xx, I joined Dr. xx laboratory at xx, where I have
been studying xx since year x. Recently, I, together with my colleagues in
xx lab, have made some progresses on understanding the role of x in x (
journal..).
In order to continue my research career in the US, I am currently in the
position of petitioning for US residency. In this process, I am required to
provide reference letters from independent, internationally renowned experts
who recognize my research contribution but do not know me personally.
Since you are a distinguished scientist in both x and x research field, I am
wondering if I could invite you to be such an independent referee to
comment on my contributions. It will be a strong support if you can help to
write a reference letter. I have attached my CV for your evaluation.
I am aware of your busy schedule and I am willing to compose a draft for
your review, if you prefer. Your letter would be only used for my green card
application and would not be used for any other purpose. It would be highly
appreciated if you could help.
Best regards,
Xx
2. 要review。 我也找了现在的老板和其他认识的PI帮我referral, 但是三次只成了一
次, 还是编辑又找了一圈其他人未果,才找的我。我以前的老板因为在editor board
,直接发了两篇文章给我review。其他的我是靠给编辑发信和在Editorial Manager 上
注册得到的。
我看到不少人抱怨在Editorial Manager上注册没用,不知道大家在Personal
Information 里有没有加上ORCID的link。你可以在ORCID里建立自己的profile,把发
过的文章,education的信息都添上,这就好像付了一份简历,editor可以看你是不是
qualify。
我去年10月开始要review,一开始的2个月除了一个editor回信说会考虑我,没有任何
invitation,12月有了第一个邀请,现在一共攒了16篇。除了上述两个主要渠道外,也
有本版热心人的帮助。
收到review invitation 后,认真完成,就容易有回头客。我因为长期帮老板review,
虽然都没有credit,也算是积累了些写comment的经验。我的comment一般都是三段体,
第一段总结文章的内容,第二段根据field 的研究现状指出主要的优缺点,第三段是
specific points,逐条提出具体意见和建议的相关实验。
申请绿卡真是个痛苦的过程,需要皮厚心细。与各位共勉,祝大家一起早绿。等有了结
果我再来更新我的背景和timeline。
r****y
发帖数: 263
5
收入申请书模板类别http://user.qzone.qq.com/2915799706/blog/1398824866
Petition letter (参照laoda555超长经验和hotmale的NOID回复写的):
XX , 2010
U.S. Department of Homeland Security
Citizenship and Immigration Services
RE:Applicaions: I-140 Immigration Visa Petition
Petitioner: Dr. B AA
Beneficiary: Dr. B AA (AXXXXX)
Category: Alien of Extraordinary Ability
Dear Immigration Officer:
The following is respectfully submitted in support of my petition for
classification as a qualified immigrant under the First Preference as
an
alien of extraordinary ability. The evidence submitted in this
petition
will prove:
I. I am an alien of extraordinary ability on the basis of the
following
facts:
a. I have authored important research articles in the leading
journals
in biomedical research field, and my publications have received
sustained international acclaims.
b. I have made original scientific contributions of major
significance
to my field of endeavor.
c. I have received lesser nationally and internationally recognized
awards.
II. I will continue work in the area of extraordinary ability in the
United States.
III. My future stay in the United States will substantially benefit
this
country.
I. I AM AN ALIEN OF EXTRAORDINARY ABILITY
A. AUTHORSHIP OF SCHOLARLY ARTICLES IN PEER-REVIEWED JOURNALS IN MY
FIELD
I have published 16 scientific articles in various prestigious peer-
reviewed journals with worldwide circulation, and I co-invented 5
patents. In addition I have 2 research manuscripts and 2 book chapters
are under review. A full list and the copies of my publications and
patents are packed as Exhibit 2 and 3. The general information of my
articles (including published and submitted) is:
Original Research Article: 16 (9 first-authored, 5 second-authored, 1
fourth- authored and 1 sixth-authored)
Review: 2 (1 first- authored and 1 second-authored)
Book Chapter: 2 (2 first-authored)
Patent: 5 (Co-inventor)
1. My articles are published in the leading journals in biomedical
research field:
A widely used measure of the importance of a particular scientific
journal is the Thomson Scientific Impact Factor (IF) published by
Thomson Reuters. The Impact Factors of several journals, which
published my articles, are as Table 1:
Table 1
Journal Title 5-Year Impact Factor (IF)
A Journal 33.0
B Journal 12
D Journal 5.6
C Journal 1.9
Below is the detailed description of the significance and importance
of
these journals:
“A Journal contains invited critical reviews of physiological topics
as
well as reviews in biochemistry, nutrition, general physiology,
biophysics, and neuroscience. Reviews are invited from leading
scientists worldwide by an American Editorial Board and a European
Editorial Committee. A Journal has the highest impact factor (33.0) in
the ISI physiology category, ranking 1st among 78 physiology
journals.”
[Exhibit 4.1]
“B Journal publishes reports of novel results that are of unusual
significance and of interest to researchers in the field”. “Its team
of
PhD-trained scientific editors works closely with authors, reviewers,
and the scientific editorial board to ensure that the high standards
of
the journal are maintained while publishing breaking discoveries and
the
best in molecular mechanisms” [Exhibit 4.2]”
D Journal is another highly respected journal. “This Journal publishes
papers based on original research that are judged, after editorial
review, to make a novel and important contribution to the
understanding
of any area of biochemistry or molecular biology” [Exhibit 4.3].
“C Journal is one of the leading journals in xxx in the world. The
Journal publishes papers of the highest scientific merit and widest
possible scope on work in ….” [Exhibit 4.4]
2. My publications have had a significant impact in my field:
2.1. My publications have been frequently cited by other scientists.
The
citation search results retrieved from Google Scholar on April 17,
2010
[Exhibit 5] are summarized as following [Exhibit 5.1]:
Total citation: 234
Total independent citation: 215
Total citation of 1st authored articles: 133
Total independent citation of 1st authored articles: 122
2.2. According to ISI Web of Knowledge, my 5 articles written in
English
have been cited 163 times [Exhibit 6.1] (155 Independent citations).
The
annual citing articles of these papers (earliest publication year is
2004) increased from 5 in 2005 to 47 in 2009 [Figure 1 and Exhibit
6.2].
Thus, it is expected that there will be more citing articles in
future.

    Figure 1 Citation distribution by year
(* Analysis results of ResearcherID ISI Web of Science)
2.3 My articles are frequently cited by the most prestigious journals
including: Nature, Cell, Nature Review Cancer and Science. The impact
factors for the journals in which my work has been cited are
summarized
partially as Table 2.
Table 2
Journal Title 2007 Impact Factor (IF)
Nature 31.4 Exhibit 11.1
Cell 31.3 Exhibit 11.2
Nature Review Cancer 30.7 Exhibit 11.3
Science 28.1 Exhibit 11.4
Trends in Biochemical Science 14.1 Exhibit 11.5
Genes & Development 13.6 Exhibit 11.6
Trends in Cell Biology 13.4 Exhibit 11.7
B Journal 12.9 Exhibit 11.8
BBA-REV CANCER 9.3 Exhibit 11.9
Proc Natl AMAd Sci USA 9.6 Exhibit 11.10
PLoS Pathogens 9.1 Exhibit 11.11
Cell Death & Differentiation 8.3 Exhibit 11.12
Cancer Research 7.5 Exhibit 11.13
Oncogene 7.2 Exhibit 11.14-11.15
3. My publications have received sustained international acclaims
As indicated below, my publications have received sustained
international acclaims. The scientists who have been citing my work
are
from 31 countries and territories, which are distributed in North
America, Asia, Europe, Australia, South America and Africa (Table 3
and
Exhibit 6.3-6.7).
Table 3
COUNTRY/TERRITORY RECORD COUNT %
AUSTRALIA 5 2.76
BELGIUM 3 1.66
BRAZIL 8 4.42
CANADA 5 2.76
CHINA 15 8.29
DENCARK 2 1.10
ENGLAND 8 4.42
FRANCE 6 3.31
EGYPT 1 0.55
INDIA 1 0.55
IRELAND 1 0.55
ISRAEL 4 2.21
ITALY 9 4.97
JAPAN 13 7.18
LEBANON 1 0.55
MEXICO 1 0.55
NETHERLANDS 2 1.10
NORWAY 1 0.55
POLAND 1 0.55
PORTUGAL 1 0.55
RUSSIA 3 1.66
SCOTLAND 4 2.21
SERIA MONTENEG 1 0.55
SINGAPORE 5 2.76
SLOVENIA 1 0.55
SOUTH KOREA 2 1.10
SPAIN 3 1.66
SWITZERLAND 1 0.55
TAIWAN 2 1.10
USA 71 39.23
In summary, my publication record is extraordinary; it far exceeds the
ordinary level of achievements in the scientific community.
The reasons for the difference in the number of results retrieved from
Google School [Exhibit 7.1] and ISI Web of Knowledge [Exhibit 7.2]
are:
I. Difference database sources.
II. ISI only includes “highest impact journals worldwide” [Exhibit
7.2],
whereas Google Scholar broadly searches for scholarly literature.
B. ORIGINAL CONTRIBUTIONS OF MAJOR SIGNIFICANCE IN MY FIELD
1. I have made extraordinary progress in the field of biomedical
research. My major original contributions are summarized as follows:
1.1. I am the first scientist who identified a novel pathway by which
R
protein (R), an important anti-cancer protein was degraded. This
finding
published in B Journal in Month, Year (1st author: AA) [Exhibit 2.7].
This finding has had tremendous impact on other scientists’ work. It
has
been cited 77 occasions [Exhibit 5.2] by scientists from 17 countries
and territories [Exhibit 6.3].
This finding is one of the most important evidences of the pathway of
“XXXX”. It was cited 7 times and heavily discussed in the review
article
titled “XXX” (Bariel-Ancontre et al. 2008 BBA-REV CANCER) [Exhibit
11.9]
B Journals only publish “the best in molecular mechanisms” [Exhibit
4.2]. Even compare with the articles published in B Journal, my paper
is
still the most cited one among the articles on topic of “R protein”
[Exhibit 6.8, Table 4 and Figure 2], which clearly indicates the
importance of my finding.
Table 4
Article Title First Author Citation
AAAA Dr. AAA 77 [Exhibit 5.2]
BBBBB Dr. M 4 [Exhibit 6.9]
CCCCC Dr. P 17 [Exhibit 6.10]
Figure 2
Prof. A W N, who does not know me personally, provides an independent
evaluation of my finding: “Dr. AA is the first scientist who
demonstrated that R could be degraded by U-independent pathway. Dr.
AA’s
groundbreaking discovery about the mechanism of R protein degradation
has tremendously contributed to our understanding of the regulation of
tumor suppressors and significantly advanced the study in developing
novel therapies against a variety of human cancers through protecting
R
from degradation.” [Exhibit 8.2]
1.2. I have uncovered the mechanisms by which oncoprotein MMM
inactivates R protein. These extremely important findings established
the role of MMM in R-related human disease including human cancer.
These
findings resulted in two 1st authored articles (AA et al. 2004 D
Journal
[Exhibit 2.8]; AA et al. 2005 B Journal [Exhibit 2.7]). Among 11
original research articles on topic of “R and MMM” published in one
year, 1) my work was published in journal with highest impact factor
and
2) my article is the most cited one and the citation frequency of my
work is 3.6 times higher than the average level [Figure 3 and Exhibit
6.11-6.12]
Figure 3
Prof. LR provides an independent evaluation of my finding: “This study
is of great significance both in cancer biology and for the
development
of novel therapies against a variety of human cancers. Since the
inactivation of the R and p pathways is responsible for the majority
of
human tumours, her study suggests that inhibition of MMM’s full
activity, not only ubiqitination function, would be more effective and
would have wider application for preventing the uncontrolled growth of
cancer cells.” [Exhibit 8.3]
Prof. J Y also provides an independent evaluation of my work: “Her
finding is a milestone in this field and will have a great impact on
developing therapeutics to inhibit oncoprotein MMM and protect tumor
suppressor protein R, which in turn will protect human life from
cancer.” [Exhibit 8.1]
1.3 I have revealed high infection rate of GGG virus (H) in XXX
carcinoma. This finding was presented at xxxx International and Nth
National H cancer Congress held in XX city, China and received the
“Best
Poster” award [Exhibit 10.12-10.14]. This finding was published in
Shanghai J XXX (1st author: AA). [Exhibit 2.16]
1.4 I have demonstrated that H onco-protein activate NNN in YYY
lesions.
This finding was presented in the 1st Chinese Conference on Oncology
in
xxxx and received “Excellent Paper Award” [Exhibit 10.1]. This finding
was published in Chin J XXX (1st author: AA). [Exhibit 2.14]
1.5. I have demonstrated that the infection of H is an important cause
of YYY cancer. This finding was published in the leading journals in
YYY
surgery: C Journal (1st author: Z Z, 2nd author: AA) [Exhibit 2.9 and
Exhibit 4.4]).
This article has been cited 33 times (32 independent citations)
[Exhibit
6.13] by scientists from 16 countries and territories [Exhibit 6.14]
as
retrieved from Scopus on April 3, 2010. The citing articles include 8
reviews and 1 book chapter [Exhibit 6.14]. The citation frequency of
this article is 7 times more than the average level of the same topic
articles published from 2004 to 2005 (33 vs. 4) [Exhibit 6.15].
“This paper is the first and only available document about China for
the
international epidemiological study in this field” (Letter from Prof.
Z
Z [Exhibit 8.4].
1.6. I have revealed the mechanisms underlying oncogenic effect of H
in
YYY cancer. H is also an important cause of xxx cancer. I clarified
for
the first time that the H disrupt different cell cycle regulation
pathways in YYY tissue and xxx tissue. This finding is published in C
Journal. (1st author: AA) [Exhibit 2.6].
This paper is the most cited article among three same topic papers
published from 2005 to 2006 [Exhibit 6.16].
Prof. A W N: “Dr. AA not only demonstrated significant association of
H
with YYY cancer but also revealed the molecular mechanisms of H’s
oncogenic function, which clearly linked H infection and YYY cancer.
Her
breakthrough discovery helps greatly in developing new strategy such
as
using H vaccines to prevent YYY cancer, which now has been used in
clinical trials.” [Exhibit 8.2]
2. My finding has been used as a basis to design, test and support
important research works by numerous famous research laboratories
worldwide.
Dr J A, Researcher at Johnson & Johnson Pharmaceutical research and
Development in Belgium, in his article published in N Journal writes,
“In agreement with our observation, recently AA et al (2005) published
that MMM promotes P-dependent U-independent degradation of the R
protein. In their study, MMM ablation results in R accumulation and
inhibition of DNA synthesis. Our data suggest that antagonists of the
N-
terminal MMM domain have similar effect.” [Exhibit 11.7].
Dr. M-H L, Professor at the University of Texas, MD Anderson Cancer
Center, in his article published in M Journal writes, “Recently, MMM
is
involved in promoting the degradation of tumor suppressor R proteins
(AA
et al., 2005…), ad thus contributes to cancer development…. MMM has p-
independent function in degrading R (AA et al., 2005). It is shown
that
disabling MMM leads to inhibition of DNA synthesis in an R-dependent
pathway (AA et al., 2005). That MMM can degrade R in a P-dependent
pathway provides a possible explanation for such a phenomenon (AA et
al., 2005…). We show that hhh is required to block MMM-meditated R
degradation …, which is consistent with its role as a negative
regulator
of MMM and cell cycle in general.” [Exhibit 11.8].

3. My preeminence in my field has been significantly recognized, which
is evidenced by being called upon to provide peer-review for a number
of
journals/Research Association as listed Table 5:
Table 5
Name of Journal/ Research Association Location of publisher
E Journal USA Exhibit 9.1
F Journal Canada Exhibit 9.3
G Journal Italy Exhibit 9.5
H Journal Slovakia Exhibit 9.7
I Association USA Exhibit 9.9
Below is the detailed description of these journals/Research
Association:
E Journal is the official journal of the International Society for W
Research. “Impact fact of 5.25 makes E Journal one of the top ranked
journals in the ISI's W Systems Category.” [Exhibit 9.2]
F Journal is “the best known canadian research journal in its field,
F
Journal, which publishes articles in English and French, enjoys a wide
international readership because of its in-depth research articles
that
explore every aspect of general biochemistry, its up-to-date coverage
of
experimental cellular and molecular biology, and its comprehensive
special issues dedicated to subjects of current interest.” [Exhibit
9.4]
“G Journal is devoted to original research on the organization of
cells, their components and extracellular products, at all levels
including the grouping and interrelations of cells, in tissues and
organs. Emphasis is placed on cell biological aspects of structure,
function and behaviour of cells, and primarily morphological accounts
must include substantially new information of general interest.”
[Exhibit 9.6]
“H Journal publishes high-quality research papers in the fields of
microbial, plant and animal sciences. Microbial sciences papers span
all
aspects of Bacteria, Archaea and microbial Eucarya including
biochemistry, cellular and molecular biology, ….” [Exhibit 9.8]
I Association is a non-profit organization in the United States that
fosters appropriate health care in an effort to reduce disability and
deaths caused by J disease. A leading priority of the I Association is
to fund research that increases an understanding of the causes,
treatments and prevention of J diseases and stroke. It is recognized
as
a worldwide leader in J science. Top J scientists throughout the world
include Nobel Prize recipients are wholly or partially funded by the I
Association. [Exhibit 9.10] The qualifications of peer reviewer of I
Association include 1) minimum assistant professor career level or
equivalent, 2) nationally recognized competence in one or more fields
of
biomedical research and 3) consistent record of peer reviewed
publications within the past five years. [Exhibit 9.11]
In summary, I have made extraordinary progress in the field of
biomedical research as noted by Prof. LR (Queen's University, Canada
[Exhibit 8.3]): “Dr. AA is truly a researcher of outstanding ability
who
has made highly significant and long lasting contributions to the
field
of cancer biology. She is an invaluable asset to the international
research community. Her unusual accomplishments have put her on the
very
top of researchers in her area.”
C. I HAVE RECEIVED LESSER NATIONALLY and INTERNATIONALLY RECOGNIZED
AWARDS.
Due to my distinguished achievements, I was honored two nationally
recognized and one internationally recognized awards: 1) “Excellent
Paper Award” of the 1st Chinese Conference on Oncology (China, xxxx)
2)
“State Natural Science Award” granted by Ministry of Education (China,
2005), and 3) “Best Poster” Award of xxxx International and Nth
National
H cancer Congress (China, xxxx):
1. “Excellent Paper Award” of Chinese Conference on Oncology.
My research article entitled “XXX” won “Excellent Paper Award” at the
1st Chinese Conference on Oncology in xxxx [Exhibit 10.1].
“Chinese Conference on Oncology is the highest-level academic forum in
Chinese oncology field, representing the newest development and
frontiers of Chinese oncology science”. [Exhibit 10.2] It is sponsored
by Chinese Anti-cancer Association (CACA) [Exhibit 10.3] and Oncology
Society of Chinese Medical Society, Co-Sponsored by International
Union
Against Aancer (UICC) [Exhibit 10.4]. The 1st Chinese Conference on
Oncology was held in Beijing, xxxx. Since then, this conference is
held
every two years in China.
“Excellent Paper Award” is honored to less than 2% candidates (for
Example, the Nth Chinese Conference on Oncology in 2010 had received
more than 1600 manuscripts and only 28 were honored “Excellent Paper
Award” [Exhibit 10.5]). The purpose of this award is to stimulate the
development of Oncology and to enhance the ability of scientists on
clinic medicine, education and basic research in Oncology. Applicant
should be the first author of manuscript and this award is only
granted
to those who have made original and breakthrough discovery in tumor
basic research or the finding has great value in medical treatment or
healthcare [Exhibit 10.6].
2. A major national-level award: the “State Natural Science Award”
granted by the Ministry of Education of China [Exhibit 10.7].
This is one of the highest nationwide awards granted by the most
prestigious agency in the field of science and technology in China.
Scientists from every University in China can compete for this award
by
submitting their research results, with only less than 0.1% of
scientists (in total about 0.7 million faculty members in more than
1600
universities in China) having the opportunity to receive the award
every
year.
“The four major science and technology award at state level refer to
the
State Natural Science Award, State Technical Invention Award, State
Science and Technology Advancement Award and International Science and
Technology Cooperation Award of the People's Republic of China.”
According to the selection criterion [Exhibit 10.10], State Natural
Science Award will be “accorded to citizen who formulates the
phenomena,
characteristics and law of nature and makes significant scientific
discovery in basic research and application basic research. The
judging
standard will be close to the general international conventions, and
the
scientific level, scientific value, the number of published articles
on
domestic and foreign authentic periodicals and the number of quotation
thereof will be important indexes, and international scholars will be
invited to participate in the judging as appropriate”.
It is a great honor to a scientist in China to be granted this award.
In
2005, the research project in our group entitled “XXX” was granted the
above award. I am one of the key contributors [Exhibit 10.9].
Regarding my contributions to this project, Prof. Z Z, the leader of
this project, wrote, “Dr. AA has made the key and critical
contributions
to these projects. Her publications are the most important and basic
part of our application for this award.” [Exhibit 8.4].
3. “Best Poster” Award at the xxxx International and Nth National H
cancer Congress (China)
I have received “Best Poster” Award at xxxx International and Nth
National H cancer Congress held on xx Month, XX year, Shanghai, China.
[Exhibit 10.12 and 10.13]
xxxx International and Nth National H cancer Congress received a total
of nearly 400 manuscripts from 19 countries and territories (China,
Hong
Kong, United Kingdom, United States, Canada, Japan, Netherlands,
Sweden,
Switzerland, Singapore, Austria, Poland, Macedonia, Portugal, Israel,
Yugoslavia, Indonesia, Belgium and Egypt. [Exhibit 10.14]. “Dr. AA
received Best Poster award at xxxx International H cancer Congress.
More than 300 clinical doctors and scientists worldwide presented
their
work at that congress held in Shanghai, China xxxx. The best poster
award was honored to the best scientist who had made outstanding
contributions to the development and advance of H cancer research
among
200 poster presentations. Dr. AA’s work was highly appreciated by
experts and she was the only Best Poster award winner at that
congress.”
(Letter from Prof. Z Z [Exhibit 8.4])
II. I WILL CONTINUE WORK IN THE AREA OF EXTRAORDINARY ABILITY IN THE
UNITED STATES.
I am currently a full-time faculty member at University of xxx
[Exhibit
1.2]. I am independently conducting a critical research focus on the
mechanisms of XXX cell growth and differentiation.
Prof. A B C, Director of XXXX; Chief, Division of CCC, NNN School, MA,
USA [Exhibit 8.6]
“Dr. AA is currently an ZZZ (title) in the Dept of Medicine, Division
of
CCC. This is a faculty position at X University requiring creative
productive high quality research, competence in the development or
utilization of new approaches and techniques for the solution of
professional problems and extended recognition by peers. Dr. AA’s
previous success and her outstanding performance at X University make
her uniquely qualified for this position.”
III. MY FUTRURE STAY IN THE UNITED STATES WILL SUBSTANTIALLY BENEFIT
THIS COUNTRY.
My permanent residence in the United States would greatly improve the
international competitiveness of the United States in the field of
biomedical research.
Prof. A B C: “…Dr. AA’s skills and experience are valuable assets to
the
US J research community. She is playing a key role in the most
important
ongoing projects at xxx. Her continuous participation and unwavering
devotion to these tasks are very critical for success of these
projects.
In terms of research in J research, other countries have continued to
produce outstanding scientists. Unfortunately, the quality and
quantity
of our young domestic scientists has declined in the US and our
nation’s
once undisputed scientific superiority is being threatened. Give our
dependence on foreign source for our research, we need talented
scientists like Dr. AA to continue the significant work. A delay in
the
process will hamper the US national interest. ” [Exhibit 8.6]
Prof. E F G, XXX Chair in xxx [Exhibit 8.5]
“Dr. AA has been generating exciting data and results of these works
will soon be published in leading and peer-reviewed professional
journals. These findings have the potential to fill in the gap of our
knowledge in this field and will unequivocally answer the most
important
questions regarding XXX disease. It is clear to me that this research
is
on track to exert enormous impact in this field as it will greatly
advance our understanding of the molecular mechanisms of XXX cells
growth and improve the clinical management of XXX disease.”
In summary, I am an alien of extraordinary ability, proven through a
remarkable publication record, solid record of original contributions
of
major significance and my receipt of lesser nationally recognized
awards. Moreover, I will continue work in the area of extraordinary
ability in the United States and my work will prospectively benefit
the
United States to a substantial degree.
I sincerely hope that I have provided you with the information and
documentation necessary and sufficient to approve my I-140 petition. I
deeply appreciate your kind consideration and care of this
application.
Should you have any question, please inform me at your earliest
convenience. Thanks!
Sincerely yours,
c********3
发帖数: 4531
6
zan
b***f
发帖数: 128
7
怒赞!
r****y
发帖数: 263
8
收入推荐信模板类别http://user.qzone.qq.com/2915799706/blog/1398826316
Angellee推荐信1
U.S. Departmentof Homeland Security
Feb 19, 2013 Citizenship and Immigration
Services
RE: OpinionLetter to SupportI-140 Immigrant Visa Application Applicant:
Angellee, Ph.D.
Fields of Expertise: Chemical Biology, Antibody Engineering, Protein
Therapeutics, Nanobiotechnology, and Cancer Therapy
Dear Sir/Madam:
I am writing this letter as the Ph.D. advisorof Dr. Angellee in the
strongest support of her application for U.S. Lawful PermanentResident
status as an Alien of Extraordinary Ability. Dr. Angelleeis currently a full
-time postdoctoral researchfellow at the University of Texas, Austin.She is
a research scientistwith extraordinary abilities in several challenging as
well as important areas of biomedical research: chemical biology,antibody
engineering, proteintherapeutics, nanotechnology, and cancer therapy.Her Ph.
D. researchwork in engineering multivalent antibody nanorings for drug
deliveryprovided necessary supporting data and led to two NationalInstitute
of Health(NIH) research grants (R01 xxx and R01 xxx) awardedto my group, and
is essential to developthe protein therapeutics as novel drug delivery
systemfor cancer therapy,which play a vital role in the health care of the
United States.
As for myself,I am the Endowed Chair and Professorin Medicinal Chemistry at
University of Minnesota. I have served as the Directorof Chemical &Biology
Graduate TrainingProgram, Director of Chemical Biology Initiative, and
AssociateDirector of Nanobiotechnology Initiative at University of Minnesota
. I am the Associate Editorof Molecular Pharmaceutics in American
ChemicalSociety since 2003. I receivedmy Ph.D. degree from Duke University
in 1987 and National Institutes of Health postdoctoral training in the
Pennsylvania State University from 1987 to 1991. I have publishedover
eighty scientific papers. I have extensive experience as a mentorfor
undergraduate and graduate students, MD/PhD students, postdoctoral
researchfellows, medical fellows,and junior facultymembers from University
of Minnesota over the past 20 years. Many of them are successful, productive
, and independent researchscientists at universities, research institutes,
medicalcenters, and industry.
In my opinion,Dr. Angellee is an extraordinary research scientist possessing
excellent research techniques, who certainly ranks among the few best
scientists at the very top of her field. Dr. Angellee’sresearch findings
are criticalto the development of our current researchprogram supported by
National Instituteof Health. The ongoing research projectsare of the utmost
national interest to the United States with regards to cancer therapy, and
are not merely for making profitsfor the university.
Dr. Angellee is an impressive scientist of extraordinary ability who is one
of the few who has risen to the very top of the field. Dr. Angellee carried
out her graduateeducation training in my group from 2004 to 2010. We
interacted on a daily basis, and I am very familiarwith her attributes in
research, as well as her other academicpursuits. Dr. Angelleereceived her
bachelordegree in 2004 from University of Science and Technology of China,
which is one of the top universities in China. During this time, she worked
as a research assistant at the Key Laboratory of Structure Researchof
Chinese Academyof Sciences. Her research topic mainly focused on
nanoparticles. Dr. Angellee and her colleagues developed a hydrothermal
method for controlling the morphology of Zinc Oxide and CupricOxide
nanoparticles, which have greatpotential applications in optical devices.She
graduated with an exceptional successful track record of achievements and
contributions for an undergraduate student, with publications in peer
reviewedinternational journals, including Solid State Sciences, Crystal
Growth & Design, and Journal of Solid State Chemistry. This is why I
selected her to join my group in December 2004. Her expertise in
nanotechnology made her an excellent additionto our researchgroup
participating on nanobiotechnology and development of multivalent antibody
nanorings. Dr. Angelleehas made a major impacton the productivity of my
research group.Dr. Angellee made truly impressive progresson her research
project, particularly in developing novel methods for the development of
ChemicallySelf-Assembled Nanoparticles (CSANs)for the displayof recombinant
antibodies. She was the first to characterize these unique structures both
biologically and biophysically. These antibody nanoringshave been found to
be especially useful in acting as vehiclesfor the delivery of
cytotoxicagents, such as anti-cancer drug, radionuclide, oligonucleotide,
etc., to the cancercells, while limitingthe toxicity of the delivered agent
to the normal cells.She is the first authorof two publications in Angewandte
Chemie International Edition, and Journal of American ChemicalSociety. She
is a co-author of one publication in British Journal of Cancer. She is also
a co-author of a book chapter in the textbook“Methods in Molecular Biology:
Nanoscale biocatalysis”. As a furthertestament to the impact of Dr.
Angellee’s research, a start-upcompany has been formed to commercialize
CSANS as both imaging and therapeutic agents.
In the last year of her PhD research, Dr. Angellee joinedthe Department of
Late StagePharmaceutical & Processing Development at Genentech for a co-op
program. Within six months, Dr. Angellee was able to develop an
innovative approach to improveparvovirus filtration efficiency and product
qualityduring drug manufacturing process.Many therapeutic proteinsand
antibodies are currently producedfrom mammalian cell lines that are prone to
have viral contamination. The incorporation of a robustparvovirus
filtration clearance step in the drug purification processes is criticalto
provide efficientviral safety of drug products.However, small pores of the
parvovirus filters can easily get clogged,leading to low membrane
permeability and fouling, therefore substantially limit the filter capacity
and increase the cost by frequent filter replacement for a given batch. The
formulation strategy based methodology, which was developed by Dr. Angellee,
prevent membrane fouling of the parvovirus filter, significantly
enhancefilter capacity, decrease processing time in manufacturing and
therefore the drug cost. Dr. Angellee’s outstanding research work in
Genentech has led to one patent application currently under reviewand two
manuscripts in preparation.
In the November of 2010, Dr. Angellee joined Dr. XXX and Dr. XXX’s group to
continue her scientific career in the area of drug discovery and
development. Dr. Angellee and her colleagues successfully developed a new
yeast-surface-display based high-throughput screeningmethod of
proteaseevolution for alteredspecificity and activity. One of Dr. Angellee’
s projects is aimed at developingnew generation of therapeutic protease to
precisely cleaveprotein targets involvedin disease progression. Her project
is intellectually and technically challenging, demandinga combination of
knowledge, experience, and techniques in protein engineering,
molecularbiology, medicinal chemistry and strong background in chemical
biology.Based on what I know of her research, Dr. Angellee’s expertiseis
essential for the continuation of this importantproject.
Dr.Angellee has made importantinnovative and originalscientific
contributions of major significance to the field of antibody engineering and
cancer therapy.Her important novel research findingsgained sustained
national/international recognition. As a criticalscientist in my research
group,Dr. Angellee has made breakthroughs in her projectsthat will
definitelybenefit the healthcare of the United States. Over the last two
decades, important progress has been made in the excitingfield of
antibodytherapeutics. Based on the innovative development of antibody
engineering methodologies, antibodies have become an important class of
human therapeutics with 28 monoclonal antibodies being approvedin either the
US or EU and actively marked by June 2011. Antibodies are used to treat a
wide range of diseaseconditions, including cancersand autoimmune disorders
being the most common targets.Dr. Angellee’s researchfocused on developing
a new generation of antibody scaffoldwith increased efficacyand novel
functionssuch as actingas vehicle to deliver anti-cancer drug for cancer
therapy.
When antibodies are used for in vivo imaging or as vehiclefor delivering a
cytotoxic agent (radionuclide, drug, or toxin), fast blood clearance of
untargeted antibodies is demanded to avoid non-target tissue binding.
Because of the existenceof constant fragments and large molecularsize,
intact monoclonal antibody exhibits a very long circulation time, which
causes dose-limiting bone marrow toxicitywhen applied therapeutically, as
well as high background radioactivity or fluorescene during imaging.
Furthermore, the constant fragmentsof monoclonalantibodies are generally
undesirable for drug delivery, since they can mediate toxicities due to
cytokine release in some circumstances. As such, it would be most
desirableto develop the methods of engineering small recombinant antibodies
containing only minimalbinding fragments. The methodology of chemically
induced dimerization to assemble multivalent antibody nanorings, developed
by Dr. Angellee, fulfills this need, and represents a major step toward
buildingan antibody scaffoldsystem for robust targeted cellular and tissue
drug delivery.
Dr. Angellee engineered the multivalent antibodynanorings that can be
assembledand disassembled by chemically controlled method.To my knowledge
this is the first example reportedof a method to reversibly chemicallyself
assemble antibodies and provides evidencethat they bind better than parental
antibody at equimolar concentrations. Since the molecular weight and
dimensions of engineered antibodies have a significant influenceon their in
vivo avidity,biodistribution, and pharmacokinetics, the method developedby
Dr. Angellee, which enables these parameters to be alteredtemporally by
chemically controlled assembly and disassembly, would in principle
enhancethe therapeutic and diagnostic utilityof recombinant antibodies.
The multivalent antibodynanorings, developed by Dr. Angelleein my
laboratory, represents an important advance in drug deliveryfor cancer
therapy.Dr. Angellee has demonstrated that anti-CD3 antibodynanorings are
able to specifically bind to CD3+ cells, undergoclathrin-dependent
endocytosis and be internalized by T- leukemia cells. In comparison, the
engineered antibodynanorings neither activate normal T cells nor are
apparently internalized. In addition, this novel approachis applicable to
other antibodies and can be used to further elucidate the role of valency
and receptor cross-linking on cell responses.Thus, Dr. Angelleehas
successfully made use of her chemical biology and nanobiotechnology
background and applied them to antibody engineering and cancer therapy.
Dr. Angellee’s innovative researchcontributions have been recognized as
extraordinary by her peers. Her research achievements have national and
international impact on leading edge development of biomedical scienceand
improve healthcare, which is one of the most important nationalinterests of
the United States. Dr.Angellee has published importantscientific papers in
leading academicjournals in the field, such as AngewandteChemie
International Edition, Journal of American Chemical Society, British Journal
of Cancer,Solid State Sciences, Crystal Growth& Design, and Journal of
Solid State Chemistry, and her publications have been referenced by other
investigators. As an authorof over eighty publications and a journal editor,
I am very familiar with these peer reviewed international scientific
Journals. For instance, Journal of AmericanChemical Society andCrystal
Growth & Designare published by American Chemical Society (ACS) Publication
Division, which ranks No.1 in terms of frequency of citation among the seven
core chemistry categories. Angewandte Chemie International Editionis a peer
-reviewed scientific journal of the German ChemicalSociety with impact
factor of 13.46, the highest valuefor a chemistry-specific journal that
publishes original research. British Journal of Cancer is a professional
medical journal of cancer research, publishedby the Nature Publishing Group.
The Journal of Solid State Chemistryand Solid State Sciencesare the
officialjournals of Elsevier, which is the world’s leadingpublisher of
scienceand health information and serves more than30 million scientists,
students, and health and information professionals worldwide. Her
publications have been widely and frequentlycited by prominentscientists
worldwide: France, Germany, England, UnitedStates, Canada, Iran, China,
Japan, Thailand, India,Netherlands, Sweden, Russia,and South Korea. It is a
strong evidence of international recognition of Dr. Angellee‘s
extraordinary researchwork.
Dr. Angellee’s significant research resultshave also been frequently
presented at national and international conferences and meetings. She was
selectedand made presentations at prestigious nationaland international
scientific meetings including the NationalMeeting of the American Chemistry
Society, Keystone Symposia Conference: Advances in Biopharmaceuticals,
Gordon Research Conferences: Bioorganic Chemistry, IBC’s Annual
International Conference: Antibody Engineering, Medicinal Chemistry Meeting
-in-Miniature, Molecular Biomimetics 3 Workshop, Annual Minnesota
Nanotechnology Conference, and NIH Training Grant Symposium etc. Based on
her revolutionary researchon antibody engineering, the Gordon Research
Conference (GRC) awarded Dr. Angellee Pfizer Outstanding Poster Award for
her project titled “Chemically controlled assembly of anti-CD3nanorings”.
This was a prestigious and highly regardedaward given at this conference
among researchers from all over the world.Dr. Angellee was also a Student
Poster
Winner at IBC’s 18th Annual International Conference, a winner of
travel grant to 236th ACS National
Meeting, and receivedStudent Scholarship from Keystone SymposiaConference.
Because of her extraordinary researchachievement, she has been
admittedinto Sigma Xi, a prestigious national scientific research society,
with full membership. Please note that Sigma Xi is an organization
designedto honor those who have made noteworthy contributions in research.
Based on her past trackof accomplishments, I confidently project that Dr.
Angellee will attain greater achievements in the future, and benefit our
country in a greater capacity than will her peers.
Additionally, Dr. Angellee has served as an expert reviewerfor eleven
international leading scientific journals, includingJournal of Controlled
Release, European Journalof Medicinal Chemistry, mAbs, Journal of Molecular
Catalysis B, Current Pharmaceutical Analysis, China Biotechnology, Journal
of Mechanics in Medicine and Biology, Journal of the ChemicalSociety of
Pakistan, Korean Journal of Chemical Engineering, Cellular and
MolecularBiology, and Protein & Peptide Letters. For example, the Journal of
Controlled Release is the official journal of the controlled releasesociety
. The Journal is the most influential and prestigious journal in the field
of drug delivery.Out of 261 journals in the Pharmacology & Pharmacy
category, the Journal ranks among the top 10 professional journals, with
total citations of 26071 in 2011, and ISI® 5-Year ImpactFactor of 7.529
.The European Journal of Medicinal Chemistryis a globaljournal that
publishes studies on all aspects of medicinal chemistry.The Journal is one
of the most influential and prestigiousjournals in the field of medicinal
chemistrywith total citationsof 11332 in 2011, and ISI® 5-Year Impact
Factor of 3.509.
In conclusion, as a Professorof Medicinal Chemistryat University of
Minnesota, I have more than 20 years of academic work in my field. During
this time, I have known, worked, and consulted with leading expertsin
chemical biologyand cancer therapy. I am aware of the most advanced work in
the fields of medicinal chemistry and cancer therapy,and I can confirm that
Dr. Angellee(i) has made important original contributions in development of
novel antibodytherapeutics, and her progress has significantly advancedthe
current research on anti-cancer drug delivery, (ii) has received sustained
nationaland international acclaimand recognition from her peersfor her
achievements in her field,as reflected by her publications in highly ranked
professional journals, presentations at leading international conferences,
citations of her scholarly papers, and selection for the PfizerOutstanding
Poster Award,and (iii) possessesa level of expertise in these extremely
challenging fields, including chemicalbiology, antibody engineering, protein
therapeutics, nanobiotechnology, molecularbiology and cancertherapy, that
makes her an extraordinary researchscientist. It is very clear that Dr.
Angelleeis a research scientist of extraordinary abilitywho is one of the
small percentages who has risen to the very top of her field.
Moreover, Dr. Angellee’s research work has a direct link and major
practical significance to the national interest of the United States, and
the benefitsof her research will be national in scope. She plays a critical
role and has made innovative and original scientificcontributions of major
significance in the researchfocusing on antibody engineering and cancer
therapy.Without any doubt,Dr. Angellee 's research has a directlink and
substantial practical value to a wide range of scientific disciplines. These
biomedical sciences make an enormous contribution to both the society and
the economy of the USA.
I hope you will considerher application favorably. Please feel free to
contactme if your need additional information. Thank you for your attention.
Sincerely,
XXX, Ph.D.
Professor of Medicinal Chemistry Director, Chemical BiologyInitiative
c******a
发帖数: 2215
9
thanks.
marked.

【在 r****y 的大作中提到】
: 收集于落地生根版
: 由remedy长期更新
: 模板收入空间备份
: 祝大家一切都顺利

l******o
发帖数: 270
10
谢谢LZ的共享精神
相关主题
贡献一篇主编给小编的支持信模板再请教:关于Journal的ranking percentage,化学的尤其请进
TSC 485 报绿,送绿装EB1a approve后PL分享
请问:怎么吹胡发表我的文章的Journal?贡献RFE模板: EB1a TSC PP RFE approved
进入Immigration版参与讨论
J****e
发帖数: 330
11
thanks for sharing!
g***t
发帖数: 198
12
赞!

【在 r****y 的大作中提到】
: 收集于落地生根版
: 由remedy长期更新
: 模板收入空间备份
: 祝大家一切都顺利

r****y
发帖数: 263
13
EB1A 追加PP RFE后TSC approved, 经验分享
开始长篇大论之前,要先感谢一下大蜜同志的热心帮助。因为背景不强,被RFE。没有
大蜜对RFE材料的严格把关和悉心修改,RFE approve的也不会这么顺利。所以本着大蜜
精神,分享一下申请中的经验教训,希望对和我背景相似的人有用,少走RFE的弯路 呵呵
1.背景:Biomed, 8 papers: 1 IF>25 (Co-1st ), 1 IF>10 (3rd ), 5 IF 2~10 (3
1st, 2 2nd ). Total citation 130+, Review 25次/19篇,杂志IF大多3~6
2.Timeline:
2013年11月开始着手DIY材料和四处要推荐信。。。
1/27/2014 efile i140
1/30 mailed evidence package
2/3 RD
2/6 mailed PP request
2/10 PP request RD
2/11 web status changed from "initial review" to "acceptance"
2/18 1st time RFE (FAX), requested for whole evidence package (估计此时PP部
门交接有问题,没找到寄过去的evidence package,个人感觉直接PP比追加PP要来得省
事,不存在交接中产生的问题.另外留FAX#能比较快的看到RFE letter)
2/20 2nd time RFE (FAX), requested for more evidence (我没来得及反应,似乎他
们又找到evidence package了,这次是真的RFE了。。。)
4/24 mailed RFE response
4/28 RFE response RD, PP clock started. web status "initial review"
5/7 email approval notice received at 9pm, web status changed from “initial
review” to “decision”
3. Petition letter outline及策略:
1)Authorship:
A. My articles are published in leading scientific journals: Table列入
authorship, journal name, journal IF及ranking,journal SJR ranking

B. My publications have significant impacts in the field: 列出文章google
scholar total citation, 和citing paper发表的journal的IF和ranking
C.My publications have received sustained international acclaims and are
superior to those published by my peers: Table列入每篇paper的引用次数,人数
,affiliation数和所在country数,最后贴上油灯图,(因为引用不高,所以列入了这
些以示impact。Citation>200的就没什么必要整这个,直接列油灯图了事)
因为总引不高,只好强调均引,比较了自己的Average Citations per paper和来自美
国Top
10学校的10位领域内professor的(后来证明这是一个败笔,详见4. RFE)
另外在ISI Web of Knowledge以不同的topic查找自己的paper,然后sort出自己paper
的citation rank,证明publication在同topic的paper中的引用是~top5%
2)Contribution:列出自己每一个research的每一项贡献(包括citation, media/
review highlight,被邀请写review,给talk之类),然后大段引用 RL和top citing
paper里heavy discussion。初次递交,只有6封 RL(4独立,1欧,1澳,2美)。因为
RL不多,就补充列出了让我review的top 10 journal editors的国际背景和email邀请
及致谢的话,证明well international recognition和contribution.
3) Judge work:Table列出review的manuscript#, journal name, journal IF, 以及
review的year (如果审稿时间跨度比较大的话可以列,如果比较密集就不要列Year了
).
另外,简要说明review journal在领域内的影响力及ranking, 以及引用 Editor
support letter里的话证明自己的贡献。(我递交了3封letter, 2个是分别在中美的中
国人,外加一个英国journal的manager)此外,有做其他award judge 的经历也列上了。
4)CONTINUOUS STAY BENEFITS UNITED STATES:引用boss RL中current 未发表
projects的贡献。
4. RFE及应对:
RFE 碰到两个问题:
1)针对contribution:
IO强调original RL里没有客观证据, 以及贡献讨论不详。所以重新补充了4封独立推
荐信,均来自美国 (1个associate professor中国人,其他都是director级别的美国
人)。1封出自research article 引用者,讨论我的paper对他的研究以及领域内其他
人工作的影响;1封出自top review 引用者,讨论我另一项research的贡献; 还有两封
出自experts详细讨论IF〉25的paper贡献(因为这篇去年刚发,没什么引用,只好搬出
两个专家分别讨论了三、四点具体贡献)。初此以外,请之前给过材料的两个director
写了一段statement,证明我的材料被应用于他们的研究中,有重要贡献。
除了列推荐信的内容,还给update的140+的所有citation进行contribution分类,并给
出了具体例子。(要感谢大蜜的RFE response模版,真的获益良多!)
2)针对Authorship:
前面我提到我比较了自己average citation per paper和全美top 10学校的教授。这点
被IO咬住了,强调那些教授的总引用都是几千。。。说不能评判我属于top small
percentage里的。应对策略就是 1]重新table列了publication journal都是top
ranking的;2]重新列了每篇paper在同类topic paper里citation是top rank的;3] 同
年比较my average citations rates和Biology area paper的Average Citation Rates
, 证明远高于平均水平;4] 列出全部10封推荐信中各专家大牛对我是top 5%或者领域
内pioneer的肯定。
最后,正面回答了IO的问题如下: (也许对同被IO刁难,和大牛们比总引用的弱case
童鞋有参考意义?其实我随便写的,大家也就随便看吧:)
“I would like to make an apology for not making it clear in the petition
letter that the aim of comparing my average citations per paper to those of
the professors from the top universities in USA was only to clarify the high
quality of my papers, not to demonstrate that I made more contributions
than these top scientists. Based on the combined evidence I showed, I have
demonstrated that my papers are the top-cited and have received more
citations than others in biology field. I believe that I belong to the top 5
% scientists in my specialty area. The scientists I listed in the petition
letter, like Dr#### and Dr. ###, are all the leaders among the top “small
percentage”, who should belong to top 0.5% or even top 0.05% scientists in
the area. I set strict publication standards as these world renowned experts
do to keep my publication quality, continue making significant
contributions in the field and hope that one day I can become one of them. ”
从来不灌水,希望这次码字对其他童鞋有点用 呵呵
r****y
发帖数: 263
14
NSC EB1A DIY 直接pp 8天批
先发个timeline
PP received: 4/16
Check cashed: 4/18
Approved: 4/24 直接从acceptance跳到post decision
背景比较复杂 chemistry专业 PhD前两年是nanomaterial 后来跳组去做nuclear
medicine, PET imaging 目前干postdoc一年
paper 11 总引用1500+ (google scholar) ISI 1300+ 列了独立引用
7篇材料方向 4篇是转方向后的 1作才2篇 而且引用少
1篇science 2作 引用 900+
2篇nano letters 2作3作各1篇
还有1篇1作的review文章发在sigma aldrich的杂志上 但没影响因子 附在exhibit
list但不在PL里claim
另外有1个pending的patent也没在PL里claim 只在推荐信里提到 没写具体的应用
我把所有文章就加上了 PL里面分析的时候也不区分了 claim领域是 chemistry and
materials science 算给转过方向的朋友打个气 IO可能并不那么仔细
review: 20 for 7 journals (IF 0.xx-7.xx) 要了3封editor verifcaton letter,1
个超低IF杂志 editorial board member
Reference: 5封 全部独立 其中3US 1Canada 1Spain 其中4位都是同胞 内容没怎么改
就给我发过来 学校都是很一般的 前后发了几十封信 答应的基本都是中国人
推荐人全部是材料方向 没有老板的推荐信 本来还要了封nuclear medicine方向的 但
后来琢磨避免不必要的混淆 就没加上
推荐信是用的版上的模板,没写推荐人具体发文数和引用数,剔除敏感词,每篇格式不统
一 字体不统一
有3篇具体提及那篇science的贡献(对应PL contribution1) 有该方向研究介绍和目前
主要问题 用了很多RL里收集来的闪光词 主要讲这项工作solve了什么重大问题 有什么
应用价值 没有太多冗余的工作内容介绍 个人觉得没必要
另外这3篇RL分别分布了contribution 2,3,4
第4篇RL用精炼的句式介绍了每个贡献
第5篇RL用了特别的格式 以一个独立推荐人的眼光 根据我的CV 吹发文/引用/review/
专利等
每个贡献的吹捧词被抄到PL里用于某段结尾 模板取自版上
大部分RL都是2页 个别3页 没附推荐人CV
PL里面重点突出contribution 工作claim了4项 media report1项 其他若干
我把1500多个引用全部看了遍 然后根据引用目的分类 这些是基于版上PL总结的
1.大段review引用并抄图
2.introduction纯吹捧性质 可能就一句 我只要闪光词
3.引用研究方法,有可能是用了类似思路做了差不多的结构 即使是用了不同材料
4.引用关键结论 用于解释结论
5.引用数据用于参照
6.纯采用合成方法 用于应用
7.NB文章引用 非introduction内容 比如nature等
8.某日本组频繁引用我若干文献 发了近10篇文章 就claim他们受我的工作启发 单独拎
出来提
没去要推荐信,我认为这么有目的反复引用足以证明他们认可你 follow你了
media report有 US news, C&EN, ScienceDaily Science News等等 因为是提及前老板
名字 就大致在contribution里提了下
Authorship就是用了EI factor,JCR,SJR排名 列了2个表 用了油灯图 然后是被nb杂志
引用又加了个表
用了ESI averge citation/Percentile进行比较 及2007 Chronicle_ Faculty
Scholarly Productivity Index 基本基于前人模板
PL一共19页,INDEX TO EXHIBITS 4页,Exhibit 400页
因为引用分析比较费时间 写好不容易 也懒得精简了 Exhibit没放全部引文目录 但那
些引文来自的国家、杂志等还是占了不少页数
总体来讲 虽然我引用比较多 细细推敲得话 缺点也很明显 我的经验是尽量把亮点放在
台面上 把易引起IO怀疑的证据弱化 除非你实在亮点不足 可以冒险加上去
个人觉得根据研究前人的PL以后 写PL无非是那么几板斧 对于写过文章的Ph.D应该是没
什么难点 就连句式都是现成的可以借鉴
之前2月初的时候找过几家律师评估 全部愿意接 chance很高 我既然有时间又急着file
还不如DIY快 话说回来就算律师不接 我还是更应该DIY 所以律师的评估无非是增强了
我的信心
准备材料过程了得到了无数帮助 绝大部分参考资料都是取自mitbbs 还要了很多PL和RL
模板 另外还加入了若干QQ群 可以即时解答 某位律所出来的兄弟还主动帮我改PL 增色
不少 这些都是我不能忘的 从去年8月开始从0攒review 然后今年2月开始找推荐人 这
个过程中国实实在在感受到了同胞们的援助 以后从自己做起 把这一传统保存下去 谢
谢大家!
s*****6
发帖数: 2379
15
赞LZ。
这个要置顶呀。
r****y
发帖数: 263
16
经验分享 EB1A TSC 补PP 12 天 APPROVE no RFE(3)和律师打交
485递交了 有点时间,继续写一下经历经验, 接着上一篇, 这次写一下和律师打交道
的经历经验, 应部分XDJM要求
其实与其说和律师打交道不如说和律师所打交道。
在我整个绿卡申请的过程中, 我曾经和多个律师大过交道, 从免费咨询到最后签协议
。有的律师给我评估的同时把自己说的天花乱坠, 我边被吓的敬而远之。 有的竟然还
比较高傲, 那就以后免谈了!多数还是比较中肯,并且很professional, 认为我是潜
在客户的都比较热情 礼貌,期待以后的合作。
我NIW的律师很细心, 我除了推荐信 以外 CL PL 都没改。 当初能过也很高兴, 毕竟
我还是学生。 后来EB1A, 问了几个律师 都认为我应再等等 先让我申请niw. 最终选了
这个律师除了他的评估, 他在专栏里发表了一个成功例子让我对他也多了一些信心。
再说通过他的照片声音, 我的直觉告诉的很值得让这个律师帮助申请。 后来合作还是
比较愉快的, 这里讲一些重要的小事
1。 推荐信, 不同所有不同的做法, 按照律师的要求写 改 就是了。 负责我案例的
律师确实花了不少功夫, 我对此挺满意的
2。 律师助理, 和他们打交道很重要,他们负责材料整理, 写cl 初稿等等, 但他们
有他们的要求, 我们可能不同仪, 但是只要大方向和我们的一直就按他们的方式做好
了, 千万不要把情绪待到和他们的交往中, 也不要受他们的情绪影响
3。 PL CL 一定要仔细审查, 我的案例由于时间紧迫, 律师 1st draft pl cl 中出
现了一些错误, 不过也可以理解, 最终最了解我们条件的还是我们自己。 2nd draft
, 律师所当作last draft, 但是我还是发现了一些错误, 当我和他们交涉时, 起初他
们非常不愿意改,甚至感觉我有质疑他们专业能力的企图, 因为他们认为他们还要走
一遍所有的程序, 但是我认为必须得改,我告诉他们我们的目标是一直的, 案例成功
了, 多我友好处对他们也是,因为他们就可以拿到另一半律师费了。 最后改了, 他
们又走了一遍所有的审核程序。虽然最后递交又推迟了一天。 不过你看, 我自己的案
例, 自己都审了一边遍了, 最初都没发现那些错误, 更何况是对案例没我们自己了
解的律师。 他们的审核程序可以说有4遍吧, 1 律师助理,2 负责我案例的律师,3
所里另一个不负责我案例的律师, 4 首席大律师。 所以质量控制我还是很满意的。
我的 EB1A 140 过了,我很高兴,比NIW过还高兴, 毕竟我还是个学生, 我们能更快
很快的那到绿卡了, 我老公招工作也更有希望了。 我对我的律师所的服务整体上还是
很满意的, 有些小的错误但及时纠正了, 这就是我们的作用嘛。他们所不大, 但我
相信只要他们继续这种敬业精神 以后也会做大的。 有的xdjm 认为我是托, 我和他们
非亲非故, 他们又不给我金钱物质回报,所以no conflict of interest to declare
at all,所以俺 不是托。。。。
祝XDJM们的CASE早点被APPROVE,我们的485今天deliver 了请XDJM们为我祈祷 祝我们
的485 CASE早点被APPROVE, 早点拿到绿卡吧。 谢谢大家!!
r****y
发帖数: 263
17
DUMMA
天天在这个版泡着,得到很多回复,包括很多扫盲问题。感谢!生死未卜,但是得在心
情一落千丈之前讲讲我明白的,以回馈这个热闹的版面。
以前老看帖子,说要如何吹吹吹。于是形成了个误区:要吹牛。越到后来越觉得要down
to the earth.申请绿卡是个law case,所以很注重字句的推敲。要证据确凿的砸在点
上。就说老三样。
我都是从别人成功失败的例子总结的。要精简:夸张点儿就是每句话都有用,每句话都
有solid evidence. IO看过那么多PL,估计最腻歪的就是说大空话,无聊的把官方那几
条句子捏来捏去的来回repeat。看deny的case最后的回复里经常看到IO说光重复那几句
没用,不要流于表面,得给evidence.人家烂熟于心的东西,你还叽里呱啦的吵吵个没
完,没啥新意,确实招人烦。
10条里要满足3条。注意,满足三条的最终目的是证明自己是top的。所以按字面上满足
了,有时还是不够的。
1)“Evidence of your authorship of scholarly articles in professional or
major trade publications or other major media.”
这个一般都出示发了多少文章。有自己署名就是authorship了。重点是发的journal要
证明是major的。一般我们会给排名。按字面上,这条就满足了。但是记住那个终级要
证明的。有的IO就说了,你作为教授薄厚就是靠发文章吃饭的,发几个文章不足为奇。
所以这里又要和什么个统计数据比,证明你比一般人发的多。为了防止有的IO把
authorship和impact混为一谈,保险起见还得略谈一下citation.
2)“Evidence of your original scientific, scholarly, artistic, athletic, or
business-related contributions of major significance to the field”
第一要证明是original。如果用文章说话,自然就证明了。如果用什么个大合唱的冠军
,就的证明你是主唱。第二就是证明这个“major significance”,也是大多数人头疼
的。惯用的包括citation;最管用的是independent的。给出citation盖及面有多广,多
少国家,多少机构,多少牛杂志。这个底子好的话,google,scopus啥的轻松给出。或
者跟什么percentile比一下,证明你的文章是top引用的。如果底子薄就得深挖,有什
么牛人牛校引用了,怎么引用的;最好是把你的东西作个典范来引用的,大段评论的。
IO喜欢的还包括你的东西如何被别人实际应用了,并且达到了很好的效果。这个一般用
RL说明。有个陷阱就是,不要让推荐人一味强调你对他/她个人的project有多大贡献;
在某个地方要说你的成果对这个领域包括他/她的工作的影响。否则,IO又说了,说了
半天,你做的就对那一个地方的一个人有用,没普遍性。如果没有数据让IO折服,就得
用十分具体生动的事例让IO被你的evidence的饱满度征服。让IO觉得你做人实在有内容
。在这个基础上再加褒奖之词。总之,要证明你的影响又广(international)又深(made
a difference/change),才构成major significance。
3) “Evidence that you have been asked to judge the work of others, either
individually or on a panel”
有时较真的IO会要求证明你是被“asked”, 所以有时光出示referee那页是不够的,
得给邀请函。如果只列review了什么,字面上是满足了。但是记住那个终极要证明的。
有的IO就会说了,review是你工作的routine,不算什么。所以就得加上我们申的是牛
杂志,不是随随便便找referee的。
以上只适用于正常的IO。老天保佑我别撞上个不正常的。
1 (共1页)
进入Immigration版参与讨论
相关主题
问个网页打印的问题分享我的 Index of Exhibits
Exhibit里面表加不加?贡献一篇主编给小编的支持信模板
RFE可以直接用以前的exhibits吗?TSC 485 报绿,送绿装
求助:律师说审稿的journal排名过高。请问:怎么吹胡发表我的文章的Journal?
麻烦大家帮我看一下EB1B单位的sponsorship letter再请教:关于Journal的ranking percentage,化学的尤其请进
怎么准备那个details of significance of journalEB1a approve后PL分享
攒人品,发EB1A PL模板贡献RFE模板: EB1a TSC PP RFE approved
journal 的circulation需要放在申请材料里吗回报本版I-140-NSC-PP-Approved today
相关话题的讨论汇总
话题: exhibit话题: dr话题: journal话题: research话题: angellee